The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | The new era of myeloma therapies
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, and Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, discuss novel therapies for the treatment of multiple myeloma, highlighting key combinations. Dr Mateos talks on the efficacy of B-cell maturation antigen (BCMA)-targeting therapies including bispecific antibodies, monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy, in the relapsed/refractory setting and calls for the earlier introduction of these novel targeted therapies into the treatment algorithm. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Irene Ghobrial, MD, discloses links to Janssen, Sanofi, BMS, GSK, Karyopharm and Binding Site.
Maria-Victoria Mateos, MD, PhD, has received honoraria from lectures and participated in boards with Janssen, BMS-Celgene, AbbVie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio and Sea-Gen.
